This assessment is vital because PSMA-targeted therapy, particularly PSMA-RLT, delivers radiation directly to PSMA-expressing cancer cells and therefore requires a high level of PSMA expression on the tumor to be effective. This evidence concerns the gene FOLH1 and neoplasm.